CN118584111A - Muc13作为标志物在预警肺癌骨转移中的应用 - Google Patents
Muc13作为标志物在预警肺癌骨转移中的应用 Download PDFInfo
- Publication number
- CN118584111A CN118584111A CN202410644898.XA CN202410644898A CN118584111A CN 118584111 A CN118584111 A CN 118584111A CN 202410644898 A CN202410644898 A CN 202410644898A CN 118584111 A CN118584111 A CN 118584111A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- muc13
- bone metastasis
- early warning
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 39
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 39
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 39
- 101000623900 Homo sapiens Mucin-13 Proteins 0.000 title claims abstract description 38
- 206010027476 Metastases Diseases 0.000 title claims abstract description 38
- 102100023124 Mucin-13 Human genes 0.000 title claims abstract description 38
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 33
- 230000009401 metastasis Effects 0.000 title claims abstract description 33
- 239000003550 marker Substances 0.000 title claims abstract description 7
- 210000002966 serum Anatomy 0.000 abstract description 21
- 230000004083 survival effect Effects 0.000 abstract description 12
- 239000000090 biomarker Substances 0.000 abstract description 5
- 239000000101 novel biomarker Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000002965 ELISA Methods 0.000 description 9
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 6
- 238000005406 washing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001121408 Homo sapiens L-amino-acid oxidase Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 238000010824 Kaplan-Meier survival analysis Methods 0.000 description 1
- 102100026388 L-amino-acid oxidase Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100012902 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIG2 gene Proteins 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及生物医学技术领域，公开了MUC13作为标志物在预警肺癌骨转移中的应用，所述生物标志物MUC13的富集水平在肺癌骨转移患者血清中显著上调。此外，MUC13表达水平较高的肺癌患者，其无骨转移生存时间和总生存时间显著短于MUC13表达较低的肺癌患者。因此，血清中的MUC13可被视为一种新型生物学标志物，用于预警肺癌骨转移的可能性。
Description
技术领域
本发明涉及生物医学技术领域，更具体地说，它涉及MUC13作为标志物在预警肺癌骨转移中的应用。
背景技术
肺癌作为全球范围内最常见的癌症类型之一，目前其发病率和死亡率均居恶性肿瘤之首。骨是肺癌常见的转移部位，约30％-40％的晚期肺癌患者会在疾病进展过程中出现骨转移。当前，肺癌转移的诊断高度仰赖影像学(例如CT、PET-CT等)和病理学检查，但这些方法的灵敏度和特异性尚有一定局限性，难以实现早期监测预警。同时，由于影像学检查费用昂贵，难以在长期随访中广泛应用。因此，探索并开发新型生物学标志物作为肺癌骨转移早期预警的有效工具，对于肺癌患者的定期监测具有重要意义。此举有助于及早发现并介入进行干预、从而改善肺癌骨转移的治疗效果，提升患者的生活质量。
发明内容
为了克服现有技术中所存在的上述缺陷，本发明提供了MUC13作为生物学标志物，应用于预警肺癌骨转移。MUC13是一种跨膜型黏蛋白，其在肺癌组织/血清样本中的表达明显高于正常组织/血清样本，且其高表达与肺癌骨转移密切相关。因此，MUC13的表达水平可作为提示肺癌骨转移风险的检测指标，血清MUC13可作为一种预警肺癌骨转移的新型生物学标志物。
本发明的上述技术目的是通过以下技术方案得以实现的：MUC13作为标志物在预警肺癌骨转移中的应用。
综上所述，本发明具有以下有益效果：MUC13在肺癌骨转移患者血清中富集水平升高，且MUC13表达高的肺癌患者无骨转移生存时间及总生存时间显著短于MUC13较低的肺癌患者。血清中可以检测到MUC13的表达，其表达水平与组织表达水平呈正相关，因此，血清MUC13可作为预警肺癌骨转移的新型生物学标志物。
附图说明
图1是本发明实施例中血清中MUC13在健康人群、肺癌无转移及肺癌骨转移患者中的富集程度对比图；
图2是本发明实施例中MSKCC数据库中非小细胞肺癌患者MUC13表达量高低两组的总生存时间对比图；
图3是本发明实施中MSKCC数据库非小细胞肺癌患者MUC13表达量高低两组的无骨转移生存时间对比图。
具体实施方式
以下结合附图1-3对本发明作进一步详细说明。
实施例：
实验材料：人肺癌骨转移患者血清样本，ELISA试剂盒，离心机，酶标仪。
实验方法：ELISA试剂盒检测血清中MUC13的表达水平
1)样本收集：收集患者血液后，1000×g离心10分钟后将血清和红细胞迅速小心地分离。
2)包被：用pH 9.6的CBS包被稀释液稀释MUC13抗原至5μg/ml，酶标板中每孔加入50μl抗原，4℃包被过夜。
3)洗涤：弃包被液，用PBST洗涤3次，每次3-5分钟，随后拍干ELISA板。
4)封闭：每孔加封闭液(1％BSA)250μl，37℃封闭2小时。
5)洗涤：封闭结束后，ELISA板用PBST洗涤3次，每次3-5分钟，随后拍干。
6)结合一抗：用PBST缓冲液1:1000稀释被检血清，每孔100μl，37℃孵育2小时。
7)洗涤：ELISA板用PBST洗涤3次，每次3-5分钟。
8)结合酶标二抗：洗涤后，每孔加入用PBST缓冲液1:1000稀释的羊抗鼠IgG-HRP(辣根过氧化物酶标记二抗)，37℃孵育1小时。
9)洗涤：ELISA板用PBST洗涤3次，每次3-5分钟。
10)显色：每孔加底物溶液(TMB)50μl，置室温避光显色10分钟。待显色后，每孔加入50μl终止液(2mol/L H2SO4)终止反应。使用酶标仪读取450nm的OD值，以确定血清抗体水平。
实验结果：血清中MUC13的表达检测
为了分析MUC13作为血清标志物预测肺癌骨转移的可行性，本实施例采用了酶联免疫吸附实验(ELISA)检测血清中MUC13的含量。收集41例临床患者的血清样本(其中A组为健康人群，B组为肺癌无转移患者，C组为肺癌骨转移患者)，对上述患者血清中MUC13的表达进行了ELISA检测，结果如图1所示。该结果提示肺癌骨转移的标志性蛋白MUC13在血清中的表达水平与骨转移风险呈正相关，MUC13可以作为预警肺癌骨转移的分子标志物。
为明确MUC13的生物学意义，本实施例利用MSKCC数据库和Kaplan-Meier分析方法对肺癌患者中MUC13的表达与患者的生存预后进行了生物信息学分析，结果如图2所示，对比两组患者总生存时间，结果显示，高表达MUC13的患者总体生存期较短，预后较差。同时，本实施例还分析了肺癌骨转移患者中MUC13的表达与无骨转移生存期的关系，结果如图3所示，对比两组患者的无转移生存期，MUC13表达高的患者无转移生存期更短，即高表达MUC13的肺癌患者更早发生骨转移。
综上所述，得出结论：血清中MUC13的含量可以作为肺癌骨转移的预警指标。
本具体实施例仅仅是对本发明的解释，其并不是对本发明的限制，本领域技术人员在阅读完本说明书后可以根据需要对本实施例做出没有创造性贡献的修改，但只要在本发明的权利要求范围内都受到专利法的保护。
Claims (2)
1.MUC13作为标志物在预警肺癌骨转移中的应用。
2.基于权利要求1所述的MUC13作为标志物在预警肺癌骨转移中的应用，其特征在于，所述MUC13的表达可以促进肺癌的骨转移。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410644898.XA CN118584111A (zh) | 2024-05-23 | 2024-05-23 | Muc13作为标志物在预警肺癌骨转移中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410644898.XA CN118584111A (zh) | 2024-05-23 | 2024-05-23 | Muc13作为标志物在预警肺癌骨转移中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118584111A true CN118584111A (zh) | 2024-09-03 |
Family
ID=92534737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410644898.XA Pending CN118584111A (zh) | 2024-05-23 | 2024-05-23 | Muc13作为标志物在预警肺癌骨转移中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118584111A (zh) |
-
2024
- 2024-05-23 CN CN202410644898.XA patent/CN118584111A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106885908A (zh) | 血清psmd4蛋白的检测试剂盒及其检测方法与应用 | |
| JP2015511002A (ja) | 乳癌診断用マルチバイオマーカーセット、その検出方法、及びそれに対する抗体を含む乳癌診断キット | |
| CN111733228B (zh) | 用于检测新型冠状病毒疾病是否治愈的标志物、试剂或试剂盒 | |
| CN109342727B (zh) | 食管鳞状细胞癌自身抗体分子标志物模型及其应用 | |
| JP2017133831A (ja) | 大腸がんの転移検出方法 | |
| CN115087869A (zh) | 肺癌诊断用多种生物标志物及其用途 | |
| CN110187111B (zh) | 一种用于早期贲门癌筛查elisa试剂盒 | |
| CN118604349A (zh) | 尿液中蛋白标志物在诊断乙肝病毒相关肝细胞肝癌中的应用 | |
| CN111796097B (zh) | 诊断新冠肺炎由轻症转重症的血浆蛋白标志物、检测试剂或试剂工具 | |
| CN113302495B (zh) | 膀胱癌的检测 | |
| CN108646032A (zh) | Top2a自身抗体作为肺癌诊断标志物的用途 | |
| CN108548923A (zh) | 肺小细胞癌早期特异性自身抗体panel诊断试剂盒 | |
| US20240418724A1 (en) | Molecular marker for determining very-early-stage onset risk of gastric cancer and evaluating progression risk of pre-cancerous lesion of gastric cancer, and use thereof in diagnostic kit | |
| CN107356757A (zh) | 一种口腔鳞癌早期诊断试剂、试剂盒、检测方法及应用 | |
| US20140248637A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
| CN112946274B (zh) | 颅内动脉瘤诊断血清标志物以及预测颅内动脉瘤破裂潜能血清标志物 | |
| CN102788883B (zh) | 一种用于检测抑郁症的试剂盒 | |
| DK3270163T3 (en) | PROCEDURE FOR DETECTING PROTEINS IN HUMAN SAMPLES AND APPLICATIONS OF SUCH PROCEDURES | |
| WO2017153869A1 (en) | Method for in vitro diagnosis of prostate cancer by means of urinary biomarkers | |
| CN109142730B (zh) | 一种肺癌标志物抗-psip1自身抗体及其应用 | |
| CN117031042B (zh) | 用于筛查诊断先天性心脏病胎儿的生物标志物及其应用 | |
| CN118584111A (zh) | Muc13作为标志物在预警肺癌骨转移中的应用 | |
| CN110174513A (zh) | Tgm2在制备监测克罗恩病疾病活动的生物标志物中的应用 | |
| CN117147877A (zh) | Ang1-7作为生物标志物在预测、诊断儿童脓毒症中的应用 | |
| CN119630966A (zh) | 用于对膀胱癌进行风险分层和管理的方法和系统 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |